Recently, zanidatamab received accelerated approval by the FDA based on its efficacy and potential to improve outcomes in this challenging cancer subtype, highlighting a significant advancement in HER2-targeted therapy for BTC.74, 75. This evidence concerns the gene ERBB2 and cancer.